Vertex Pharmaceuticals cut its next-period EPS forecast to $4.86 while raising its 2026 revenue outlook to $13.1–13.2 billion. New drug launches and CF-related pressure are shaping both the short- and long-term outlook.
As pricing pressure continues in cystic fibrosis, the successful launches of new products including CASGEVY, JOURNAVX and ALYFTREK will be key. The short-term earnings forecast has been cut, but underlying revenue growth expectations remain intact, with potential for recovery.
Management raised its 2026 revenue outlook to $13.1–13.2 billion while cutting its EPS forecast for the next quarter to $4.86. The company also suggested that product contributions outside cystic fibrosis could reach at least $0.5 billion.
Market expectations are based on analysis projecting revenue growth to $17.6 billion and earnings of $6.3 billion by 2029, with a mix of factors and risks supporting the maintenance of long-term profitability since 2008.
Another view is that the valuation outlook remains divided because it continues to depend in part on short-term variables such as JOURNAVX patient-support costs. Some of the company's other fair value estimates also suggest downside from the current share price.